Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950959 · ClinicalTrials.gov registry record
XACT ACE Observational Registry
A clinical trial of Tumors, sponsored by Xact Robotics.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04950959: Recruiting study of Tumors, sponsored by Xact Robotics.
NCT04950959 is a study of Tumors that is actively recruiting participants, run by Xact Robotics. The registered enrollment target is 500 participants, above the 174-participant average among 20 other Tumors trials with a reported enrollment target (187% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04950959, a study of Tumors, is actively recruiting participants, sponsored by Xact Robotics.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Compile real world data on the use of the XACT ACE Robotic System
Conditions Studied
Interventions
- DEVICE Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T
Study Locations (1)
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2026-08-01 |
What NCT04950959 shows while recruiting
NCT04950959 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 174-participant average among 20 other Tumors trials with a reported enrollment target (187% higher).
The record links to 1 condition, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T is the first listed.
NCT04950959 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04950959 about?
NCT04950959 is a clinical study titled "XACT ACE Observational Registry". Compile real world data on the use of the XACT ACE Robotic System
What is the current status of trial NCT04950959?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-10-01. Estimated completion is 2026-08-01.
What conditions does trial NCT04950959 study?
This clinical trial studies the following conditions: Tumors.
What interventions are being tested in trial NCT04950959?
The interventions under investigation include: Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T (DEVICE).
Who is sponsoring clinical trial NCT04950959?
This trial is sponsored by Xact Robotics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04950959 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04950959's enrollment target sits among peer trials
500 2nd of 20 the highest of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HP Pyruvate MRI in Cancers
RECRUITING · Phase 1
-
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
RECRUITING
-
Perioperative Risk Study
ACTIVE NOT RECRUITING · NA
-
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
ACTIVE NOT RECRUITING · Phase 2
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI